Article
Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.
JAMA network open - 2 Jan 2024
Iams Wade T, Mackay Matthew, Ben-Shachar Rotem, Drews Joshua, Manghnani Kabir, Hockenberry Adam J, Cristofanilli Massimo, Nimeiri Halla, Guinney Justin, Benson Al B
Abstract excerpt
Importance: Tissue-based next-generation sequencing (NGS) of solid tumors is the criterion standard for identifying somatic mutations that can be treated with National Comprehensive Cancer Network guideline-recommended targeted therapies. Sequencing of circulating tumor DNA (ctDNA) can also identify tumor-derived mutations, and there is increasing clinical evidence supporting ctDNA testing as a diagnostic tool....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.